Nicox’s Licensee Bausch + Lomb Receives Approval for Vyzulta in the United Arab Emirates

Nicox announced that its exclusive global licensee Bausch + Lomb has received approval for Vyzulta (latanoprostene bunod ophthalmic solution) 0.024% in the United Arab Emirates.

Now approved in 12 countries, Vyzulta is commercialized in the United States (since 2017), Canada (2019), Argentina (2020), Mexico (2020), Hong Kong (2020) and Taiwan (2021). It is also approved in Brazil, Colombia, Qatar, South Korea, Ukraine and the United Arab Emirates.

Vyzulta is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension in the United States and other territories that have the same indication. Bausch + Lomb will continue seeking approvals in territories where the clinical data package, part of the NDA, can be used for approval by the regulatory authorities.

Under the terms of the exclusive global license agreement with Bausch + Lomb, Nicox receives increasing tiered royalties of 6% to 12% on net global sales of Vyzulta plus up to $150 million in potential future milestone payments.